Snn0029    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis4

2. Amyotrophic lateral sclerosis    [ 508 clinical trials,   530 drugs,   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways]
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 508 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02269436
(ClinicalTrials.gov)
January 20158/10/2014A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALSA Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: sNN0029 infusion solutionNewron Sweden ABNULLTerminated18 Years75 YearsBoth11Phase 1Belgium;Netherlands
2NCT01999803
(ClinicalTrials.gov)
September 201422/11/2013A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALSA Phase I, Randomised, Double-blind, Placebo-controlled Study in Patients With Amyotrophic Lateral Sclerosis to Further Assess the Safety and Tolerability of Intracerebroventricular Administration of sNN0029 Infusion SolutionAmyotrophic Lateral SclerosisDrug: sNN0029;Drug: PlaceboNewron Sweden ABNULLTerminated18 Years75 YearsBoth15Phase 1Belgium;Netherlands
3NCT01384162
(ClinicalTrials.gov)
June 200923/6/2011An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral SclerosisAn Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis, Using an Implanted Catheter and SynchroMed® II PumpAmyotrophic Lateral SclerosisDrug: sNN0029Newron Sweden ABMedtronic;ICON Clinical ResearchTerminated18 Years75 YearsBoth15Phase 1;Phase 2Belgium
4NCT00800501
(ClinicalTrials.gov)
December 200829/11/2008A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral SclerosisA Double-blind, Randomised, Parallel Group Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis, Using an Implanted Catheter and SynchroMed® II PumpAmyotrophic Lateral SclerosisDrug: sNN0029;Drug: PlaceboNewron Sweden ABMedtronic;ICON Clinical ResearchCompleted18 Years75 YearsBoth18Phase 1;Phase 2Belgium